Results 151 to 160 of about 98,145 (299)

A Comprehensive Molecular and Clinical Investigation of Approved Anti-HCV Drugs Repurposing against SARS-CoV-2 Infection: A Glaring Gap between Benchside and Bedside Medicine. [PDF]

Vaccines (Basel), 2023
Bansode S, Singh PK, Tellis M, Chugh A, Deshmukh N, Gupta M, Verma S, Giri A, Kulkarni M, Joshi R, Chaudhary D.   +10 more
europepmc   +1 more source

Invalid Nucleic Acid Test Results May Limit Deceased Donor Organ Utilization

Transplant Infectious Disease, EarlyView.
Rare instances occur in which discriminatory NAT results cannot be resolved in deceased organ donor cases. When these events occur the impact on organ donation can be substantial. ABSTRACT Background Nucleic acid testing (NAT) is essential for detecting transmissible viral infections in deceased organ donors and guiding safe organ allocation.
Sara Dionne, Hillary Akana, Kaitlin Logue, Brenden O'Neale, Chris Curran, Sean VanSlyck   +5 more
wiley   +1 more source

[Mechanism and clinical significance of HBV reactivation after anti-HCV therapy]. [PDF]

Zhonghua Gan Zang Bing Za Zhi, 2022
Zeng WJ, Gao L, Xu YW, Chen XM, Wang FS, Lu FM.   +5 more
europepmc   +1 more source

Comparative Impact of Active Versus Passive Surveillance on Hepatitis C Virus Testing Uptake, Diagnosis and Linkage to Care in Low‐ and Middle‐Income Countries: A Systematic Review and Meta‐Analysis

Tropical Medicine &International Health, EarlyView.
ABSTRACT Background Hepatitis C virus (HCV) infection remains a major global health challenge, particularly in low‐ and middle‐income countries (LMICs), where limited diagnostic access and weak surveillance hinder progress toward the World Health Organization's 2030 elimination targets.
Katekani Precious Motau, Maureen Moyo Chilufya, Nyeleti P. Chauke, Smangaliso Morerwa, Kuhlula Maluleke   +4 more
wiley   +1 more source

From Screening to Therapy: Anti-HCV Screening and Linkage to Care in a Network of General Practitioners and a Private Gastroenterology Practice. [PDF]

Pathogens, 2021
Petroff D, Bätz O, Jedrysiak K, Lüllau A, Kramer J, Möller H, Heyne R, Jäger B, Berg T, Wiegand J.   +9 more
europepmc   +1 more source

Residual risk of human immunodeficiency virus, hepatitis C, and hepatitis B following implementation of sexual risk behavior‐based screening in Canada

Transfusion, EarlyView.
Abstract Background In 2022, Canadian Blood Services implemented a gender‐neutral sexual behavior‐based screening (SBBS) approach to donor deferral, replacing time‐based criteria targeting gay, bisexual and other men who have sex with men (gbMSM) and female partners of gbMSM. We assessed the impact of this policy change on human immunodeficiency virus (
Chinchin Wang, Steven J. Drews, Mindy Goldman, Sheila F. O'Brien   +3 more
wiley   +1 more source

Economic Consequences of Anti-HCV Treatment of Patients Diagnosed Through Screening in Italy: A Prospective Modelling Analysis. [PDF]

Appl Health Econ Health Policy, 2022
Marcellusi A, Simonelli C, Mennini FS, Kondili LA, PITER Collaborating Group available at http://www.progettopiter.it.   +4 more
europepmc   +1 more source

Anti-HCV [PDF]

, 2019
openaire   +1 more source

Comparing specificity and seroconversion sensitivity among major blood screening assays for human immunodeficiency virus and viral hepatitis

Vox Sanguinis, EarlyView.
Abstract Background and Objectives Accurate detection of transfusion‐transmissible infections, such as human immunodeficiency virus (HIV) and hepatitis C and B viruses (HCV/HBV), is critical to ensure blood safety, and screening assays must demonstrate high specificity and sensitivity.
Monica Chaves, Martina Schaetzl, Florina Pessl   +2 more
wiley   +1 more source

An in vitro study of an Artocarpus heterophyllus substance as a hepatitis C antiviral and its combination with current anti-HCV drugs. [PDF]

BMC Complement Med Ther, 2021
Permanasari AA, Aoki-Utsubo C, Wahyuni TS, Tumewu L, Adianti M, Widyawaruyanti A, Hotta H, Hafid AF.   +7 more
europepmc   +1 more source